Search clinical trials for: Sodium Zirconium Cyclosilicate (ZS) 5g

Total 33 results

AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia (HARMONIZE GL)

Hyperkalemia

Korea, Republic of, Taiwan, Russian Federation, Japan
AstraZeneca

Completed

ZS Ph2/3 Dose-response Study in Japan

Hyperkalemia

Japan
ZS Pharma, Inc.

Completed

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

Hyperkalemia

United States, South Africa, Australia
AstraZeneca

Completed

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

Hyperkalemia

Hong Kong
AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. (HARMONIZE Asia)

Hyperkalemia

China
ZS Pharma, Inc.

Completed

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Hyperkalemia

United States, Germany, Australia, Netherlands, South Africa, Romania, United Kingdom
AstraZeneca

Completed

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. (DIALIZE)

Hyperkalemia

United States, United Kingdom, Russian Federation, Japan
AstraZeneca

Completed

Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

Hyperkalemia

Japan
AstraZeneca

Completed

Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects (DIALIZE China)

Hyperkalemia

China
AstraZeneca

Terminated

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure (PRIORITIZE HF)

Heart Failure

United States, Canada, Brazil, Slovakia, Hungary, Romania, Poland, Russian Federation, Bulgaria
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

Hyperkalemia

United States, South Africa, Australia
AstraZeneca

Completed

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8 (ENERGIZE)

Hyperkalemia

United States, Russian Federation, Italy, Denmark
Barts & The London NHS Trust

Terminated

The ORTIZ Study: Optimising RASi Therapy With SZC (ORTIZ)

Diabetes Mellitus, Type 2 | CKD | Hyperkalemia

United Kingdom
Guangdong Provincial People's Hospital

Completed

Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy (SZC)

Hyperparathyroidism, Secondary | Hyperkalemia | Sodium Zirconium Cyclosilicate
Leiden University Medical Center
AstraZeneca

Not yet recruiting

Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 (LIBRAL)

Diet Modification | Chronic Kidney Disease | Hyperkalemia | Sodium Zirconium Cyclosilicate
AstraZeneca

Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PEDZ-K)

Hyperkalaemia

China, Germany, United States, Ukraine, Spain, Japan, United Kingdom, Canada, Poland, Romania, Russian Federation, Brazil
Brigham and Women's Hospital

Unknown

Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

Chronic Kidney Diseases | Hyperkalemia

United States
Karolinska Institutet
AstraZeneca

Completed

Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study (HELPFUL)

Chronic Kidney Disease Stage 5 | Hyperkalemia | Chronic Kidney Disease stage4

Sweden
AstraZeneca

Terminated

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Hyperkalemia

United States, Italy, Spain, Taiwan, Thailand, Vietnam, Russian Federation, Canada, Hungary, Mexico, China, Austria, Turkey, Brazil, Germany, Poland, Czechia, United Kingdom, Bulgaria, Slovakia, Peru, Ukraine, Japan, Argentina, Malaysia, ...
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

Chronic Kidney Disease | Hyperkalemia | Kidney Dysfunction

United States
AstraZeneca

Recruiting

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (CONTINUITY)

Chronic Kidney Disease | Hyperkalaemia

United Kingdom, Spain, Belgium, Italy, Netherlands, France, Germany
AstraZeneca

Recruiting

A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece (SHIELD)

Hyperkalaemia

Greece
Michael Fu
Göteborg University; AstraZeneca

Recruiting

OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (OPRA-HF)

Heart Failure | Hyperkalemia

Sweden
AstraZeneca

Terminated

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NEUTRALIZE)

Chronic Kidney Disease | Metabolic Acidosis | Hyperkalaemia

United States, Puerto Rico
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Hyperkalemia

United States, Australia
Alexandria University

Recruiting

SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

Hyperkalemia

Egypt
AstraZeneca

Terminated

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia (GRAZE)

Hyperkalaemia

United States
Peking University First Hospital

Recruiting

The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study)

Cardiac Arrhythmia | Potassium Imbalance | Dialysis; Complications

China
University of California, Irvine

Recruiting

Comparison of Potassium Binders in the ER (KBindER)

Acute Hyperkalemia | Oral Potassium Binders

United States
AstraZeneca

Active, not recruiting

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (REALIZE-K)

Heart Failure With Reduced Ejection Fraction | Hyperkalaemia

United States, Spain, Canada, Brazil, Hungary, Czechia, Ukraine, Poland, United Kingdom
AstraZeneca
Parexel

Completed

Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects

Hyperkalaemia

Germany
AstraZeneca

Terminated

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (STABILIZE-CKD)

Renal Insufficiency, Chronic | Hyperkalemia

United States, Italy, Spain, Thailand, Vietnam, Turkey, Canada, Philippines, China, Malaysia, Taiwan, Brazil, Japan, Bulgaria, Russian Federation, Poland, Argentina, Mexico, Ukraine, India, Puerto Rico
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes (MANATEE-T1D)

Cardiovascular Diseases | Type 1 Diabetes | Diabetic Kidney Disease | Endothelial Dysfunction | Insulin Sensitivity

United States

3

Subscribe